Pivotal randomized, open-label study of optune® (ttfields, 200khz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma.
Brain and spine cancer
|Eligibility criteria|| |
|Study details|| |
The purpose of the study is to test if early addition of the Optune®treatment combined with RT and TMZ as treatment for newly diagnosed GBM, significantly improves the clinical outcome of patients, compared to the standard of care, which is addition of Optune®treatment concomitant with maintenance temozolomide after the completion of RT treatment.
|Further information|| |
For more information regarding this clinical trial click here.